EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics


EyePoint Pharmaceuticals, Inc. (EYPT): $11.17

0.29 (+2.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EYPT POWR Grades


  • Sentiment is the dimension where EYPT ranks best; there it ranks ahead of 84.94% of US stocks.
  • The strongest trend for EYPT is in Momentum, which has been heading down over the past 42 weeks.
  • EYPT's current lowest rank is in the Momentum metric (where it is better than 9.48% of US stocks).

EYPT Stock Summary

  • With a year-over-year growth in debt of -27.68%, EyePoint Pharmaceuticals Inc's debt growth rate surpasses only 18.97% of about US stocks.
  • As for revenue growth, note that EYPT's revenue has grown 72.12% over the past 12 months; that beats the revenue growth of 91.16% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EYPT comes in at -39.59% -- higher than that of just 7.31% of stocks in our set.
  • Stocks that are quantitatively similar to EYPT, based on their financial statements, market capitalization, and price volatility, are DIOD, YY, AMSC, MBII, and QMCO.
  • Visit EYPT's SEC page to see the company's official filings. To visit the company's web site, go to eyepointpharma.com.

EYPT Valuation Summary

  • In comparison to the median Healthcare stock, EYPT's price/earnings ratio is 120.82% lower, now standing at -7.6.
  • Over the past 202 months, EYPT's price/sales ratio has gone down 1296.
  • Over the past 202 months, EYPT's price/sales ratio has gone down 1296.

Below are key valuation metrics over time for EYPT.

Stock Date P/S P/B P/E EV/EBIT
EYPT 2021-08-31 8.0 2.9 -7.6 -6.4
EYPT 2021-08-30 7.4 2.7 -7.0 -5.7
EYPT 2021-08-27 7.4 2.7 -7.0 -5.7
EYPT 2021-08-26 7.3 2.7 -6.9 -5.6
EYPT 2021-08-25 7.3 2.7 -6.9 -5.6
EYPT 2021-08-24 7.4 2.7 -7.0 -5.7

EYPT Growth Metrics

  • The 4 year price growth rate now stands at -69.77%.
  • Its 3 year price growth rate is now at -39.37%.
  • Its 5 year cash and equivalents growth rate is now at 85.76%.
Over the past 52 months, EYPT's revenue has gone up $32,020,000.

The table below shows EYPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 39.162 -18.611 -41.56
2021-03-31 34.271 -13.189 -44.5
2020-12-31 34.437 -14.435 -45.394
2020-09-30 35.939 -31.816 -40.335
2020-06-30 22.753 -47.724 -52.181
2020-03-31 25.841 -59.71 -50.729

EYPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EYPT has a Quality Grade of C, ranking ahead of 31.34% of graded US stocks.
  • EYPT's asset turnover comes in at 0.293 -- ranking 58th of 75 Measuring and Control Equipment stocks.
  • INIS, WTT, and BRKR are the stocks whose asset turnover ratios are most correlated with EYPT.

The table below shows EYPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.293 0.804 -0.673
2021-03-31 0.322 0.818 -0.674
2020-12-31 0.433 0.831 -0.636
2020-09-30 0.480 0.870 -0.520
2020-06-30 0.301 0.862 -0.717
2020-03-31 0.319 0.871 -0.715

EYPT Price Target

For more insight on analysts targets of EYPT, see our EYPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.20 Average Broker Recommendation 1.4 (Strong Buy)

EYPT Stock Price Chart Interactive Chart >

Price chart for EYPT

EYPT Price/Volume Stats

Current price $11.17 52-week high $15.06
Prev. close $10.88 52-week low $3.51
Day low $10.68 Volume 29,363
Day high $11.18 Avg. volume 240,902
50-day MA $9.65 Dividend yield N/A
200-day MA $9.65 Market Cap 321.36M

EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio


EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.


EYPT Latest News Stream


Event/Time News Detail
Loading, please wait...

EYPT Latest Social Stream


Loading social stream, please wait...

View Full EYPT Social Stream

Latest EYPT News From Around the Web

Below are the latest news stories about EyePoint Pharmaceuticals Inc that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting

WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet AMD has been selected for presentation at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting to be held from November 12 – 15

Yahoo | September 17, 2021

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass, Sept. 07, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals’ senior management team will present at the following four upcoming conferences: Ophthalmology Futures Euro Forums 2021 Virtual Retina ForumForum: Corporate Presentation and Panel featuring Jay Duker, M.D.,

Yahoo | September 7, 2021

EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference

WATERTOWN, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021. The presentation will be available for on-demand viewing beginnin

Yahoo | August 10, 2021

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$20.17

EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) investors will be delighted, with the company turning in some strong...

Yahoo | August 7, 2021

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 22.22% and 2.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2021

Read More 'EYPT' Stories Here

EYPT Price Returns

1-mo 10.59%
3-mo 17.33%
6-mo 11.92%
1-year 106.55%
3-year -58.48%
5-year -65.31%
YTD 69.76%
2020 -57.55%
2019 -17.99%
2018 75.00%
2017 -36.84%
2016 -64.52%

Continue Researching EYPT

Here are a few links from around the web to help you further your research on EyePoint Pharmaceuticals Inc's stock as an investment opportunity:

EyePoint Pharmaceuticals Inc (EYPT) Stock Price | Nasdaq
EyePoint Pharmaceuticals Inc (EYPT) Stock Quote, History and News - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9504 seconds.